Phenotype-oriented anticoagulant therapy for sepsis: still a work in progress

Int J Hematol. 2022 Jul;116(1):48-54. doi: 10.1007/s12185-022-03337-5. Epub 2022 Apr 5.

Abstract

Coagulation disorders ranging from subtle changes in coagulation parameters to fatal disseminated intravascular coagulation (DIC) are common in septic patients. Coagulation activation is considered to be one of the most important factors contributing to multiple organ dysfunction syndrome (MODS) in sepsis. Anticoagulant therapy is, therefore, necessary to prevent MODS, but eligibility criteria remain controversial. Sepsis is a highly heterogeneous syndrome, which could explain the negative results of clinical studies on the treatment of sepsis. Recently, sepsis has been subdivided into several phenotypes with different therapeutic outcomes. At present, septic patients with dysfunctional coagulation expressed as increased D-dimer and fibrin/fibrinogen degradation products (FDPs) are considered to be candidates for anticoagulant therapy. In this review, we aimed to describe the features of different septic phenotypes. We also discuss factors that contribute to controversies in this area, and challenges in defining which septic phenotypes are good candidates for anticoagulant therapy.

Keywords: Coagulation disorder; Phenotype; Sepsis; Thrombomodulin.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Disseminated Intravascular Coagulation* / drug therapy
  • Disseminated Intravascular Coagulation* / etiology
  • Humans
  • Multiple Organ Failure / drug therapy
  • Multiple Organ Failure / etiology
  • Multiple Organ Failure / prevention & control
  • Phenotype
  • Sepsis* / drug therapy
  • Sepsis* / etiology

Substances

  • Anticoagulants